Jyong Biotech Ltd. (MENS) Stock Price, Quote & News

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Industry: Biotechnology

Sector: Healthcare

Phone: 886 2 2732 5205

Website: jyongbio.com

Address:

No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan

superbodi Jan. 7 at 8:38 PM

$MENS today, I have built myself a new home. I will be spending my nights here until MENS pumps again! Sleep well 😴💤❄️🥶

0 · Reply

Everythingisplanned Jan. 7 at 8:35 PM

$MENS Volume, cmon!!

0 · Reply

SalmanAziz Jan. 7 at 5:52 PM

$MENS lets hope this uptrend continues

0 · Reply

sulljd74 Jan. 7 at 5:01 PM

$MENS I can feel this one in my loins.

0 · Reply

Dampskibet Jan. 7 at 4:26 PM

$MENS Its brewing

0 · Reply

Everythingisplanned Jan. 7 at 2:40 PM

$MENS

0 · Reply

wiseman88 Jan. 7 at 1:41 AM

$MENS do we expect this to make a run into what it was earlier mid year?

1 · Reply

sulljd74 Jan. 6 at 7:30 PM

$MENS now were cooking

0 · Reply

Everythingisplanned Jan. 6 at 7:30 PM

$MENS is it time!!

0 · Reply

superbodi Jan. 6 at 5:55 PM

$MENS boringggg

0 · Reply

Jyong Biotech Responds to Share Price and Volume Movement

Dec 4, 2025, 8:30 AM EST - 4 weeks ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Nov 24, 2025, 8:30 AM EST - 6 weeks ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 20, 2025, 8:30 AM EST - 6 weeks ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Sep 29, 2025, 8:30 AM EDT - 3 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 18, 2025, 8:30 AM EDT - 4 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 16, 2025, 8:18 AM EDT - 4 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Aug 22, 2025, 9:00 AM EDT - 4 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jul 26, 2025, 8:00 AM EDT - 5 months ago

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jul 22, 2025, 10:40 AM EDT - 6 months ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jun 22, 2025, 4:20 PM EDT - 7 months ago

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

ALAB ARM CAI EGG IPO IPOS JCAP

Jun 18, 2025, 5:20 PM EDT - 7 months ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 7 months ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Feb 10, 2025, 3:42 PM EST - 11 months ago

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Aug 18, 2023, 2:44 PM EDT - 2 years ago

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Aug 17, 2023, 3:16 PM EDT - 2 years ago

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Aug 17, 2023, 1:40 PM EDT - 2 years ago

Jyong Biotech IPO Registration Document (F-1)

superbodi Jan. 7 at 8:38 PM

$MENS today, I have built myself a new home. I will be spending my nights here until MENS pumps again! Sleep well 😴💤❄️🥶

0 · Reply

Everythingisplanned Jan. 7 at 8:35 PM

$MENS Volume, cmon!!

0 · Reply

SalmanAziz Jan. 7 at 5:52 PM

$MENS lets hope this uptrend continues

0 · Reply

sulljd74 Jan. 7 at 5:01 PM

$MENS I can feel this one in my loins.

0 · Reply

Dampskibet Jan. 7 at 4:26 PM

$MENS Its brewing

0 · Reply

Everythingisplanned Jan. 7 at 2:40 PM

$MENS

0 · Reply

wiseman88 Jan. 7 at 1:41 AM

$MENS do we expect this to make a run into what it was earlier mid year?

1 · Reply

sulljd74 Jan. 6 at 7:30 PM

$MENS now were cooking

0 · Reply

Everythingisplanned Jan. 6 at 7:30 PM

$MENS is it time!!

0 · Reply

superbodi Jan. 6 at 5:55 PM

$MENS boringggg

0 · Reply

superbodi Jan. 6 at 3:46 PM

$MENS new 10.000 stocks buy wall at 3.57$

0 · Reply

T45020 Jan. 6 at 3:31 PM

$MENS https://www.geneonline.com/plant-derived-compounds-genistein-and-apigenin-studied-as-dual-inhibitors-in-breast-cancer-treatment/

0 · Reply

Everythingisplanned Jan. 6 at 3:02 PM

$MENS

0 · Reply

superbodi Jan. 6 at 2:53 PM

$MENS In Dutch we have a saying called "Stilte voor de storm" which means silence before the storm. This is happening right now, and the storm will be coming for the shorts soon, arr!

0 · Reply

superbodi Jan. 6 at 2:40 PM

$MENS needs volume indeed

0 · Reply

sulljd74 Jan. 5 at 10:15 PM

$MENS just need some volume to come in. Nice accumulation.

0 · Reply

misci Jan. 5 at 7:19 PM

$MENS let’s go

0 · Reply

Everythingisplanned Jan. 5 at 7:17 PM

$MENS

0 · Reply

superbodi Jan. 5 at 3:50 PM

$MENS. Looking good. Lots of accumulation happening when you check the buy and sell orders. Whales are accumulating

0 · Reply

T45020 Jan. 5 at 3:03 PM

$MENS https://www.goodnewsnetwork.org/a-rare-cancer-fighting-plant-compound-has-finally-been-decoded/

0 · Reply

misci Jan. 5 at 2:36 PM

$MENS 🚀

0 · Reply

superbodi Jan. 5 at 7:11 AM

$MENS this will shoot up soon to the 8-12$ range.

1 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,440,831
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A